Predict your next investment

Angel Investor (Group)
bioangels.net

See what CB Insights has to offer

Investments

20

Portfolio Exits

1

About Mid Atlantic Bio Angels

Mid Atlantic Bio Angels (MABA) is an angel investor group focused exclusively on new and emerging life science companies. Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels. MABA places no geographical restrictions or requirements for presenting companies, as long as meaningful and effective post-investment monitoring of these companies can be achieved.

Mid Atlantic Bio Angels Headquarter Location

New York, New York,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mid Atlantic Bio Angels News

Aptatek Biosciences Wins “Best of the Best” at Year-End 1st Pitch Life Science Competition

Jan 6, 2020

| Source: Mid Atlantic Bio Angels NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Mid-Atlantic Bio Angels (MABA) announces today that Aptatek Biosciences (www.aptatek.com) which is developing a digital at-home health-maintenance system for Phenylketonuria, a genetic disorder that causes the buildup of certain amino acids, was named “Best of the Best” by the audience at MABA’s Annual 1st Pitch Life Science year-end event held on December 18, 2019 at the law offices of Wilson Sonsini Goodrich and Rosati in New York City. The event gathers multiple “Best in Show” winners from 2019 1st Pitch Life Science competitions. "Participating in the 1st Pitch events was both enjoyable and enlightening, as it provided us with the opportunity to not only benefit from two rounds of feedback from expert judges as well as the audience of industry members and competing companies. Events such as 1st Pitch help us refine our messaging and commercial strategy, both key to building a successful life sciences company" stated Michael Boyce-Jacino, Ph.D., CEO of Aptatek Biosciences. “We were honored to have been named the 2019 ‘Best of the Best’ among a very qualified and innovative group of companies and look forward to capitalizing on this success as we continue to grow Aptatek in 2020.” Aptatek’s goal is to enable home-based monitoring of chronic disease to improve patient outcomes through improved compliance and disease management. Currently, diagnosis and monitoring of many chronic diseases is performed in centralized laboratories, which is costly, slow, and inaccessible to millions of people globally. One such disease is Phenylketonuria (PKU), which causes a buildup of the amino acid phenylalanine and can result in intellectual disability, seizures, behavioral problems, and mental disorders if not well managed. Once diagnosed, typically at birth, PKU patients must closely monitor their phenylalanine levels using expensive and slow central lab tests for their entire lifetimes to help manage potentially severe health challenges. Aptatek’s monitoring device, allowing patients to test their phenylalanine levels at home, could be game changing for thousands of people affected by PKU because it provides clinical grade testing in an easy-to-use, portable device. "Aptatek's lab-at-home testing platform for chronic disease monitoring is fully-consistent with the ongoing trend toward lower-cost, home-based health care and has the potential to change the way the patients and physicians manage chronic disease," added Jon Popke, angel investor and MABA Steering Committee Member. About Aptatek Aptatek is a digital health company developing a novel patient-directed home monitoring system for chronic diseases ranging from inborn errors of metabolism such as phenylketonuria to chronic kidney disease. The privately held company is a spin out of Columbia University and is based in Princeton, New Jersey. About 1st Pitch Life Science 1st Pitch Life Science (http://www.1stpitchlifescience.com) is a program initiated by Mid Atlantic Bio Angels to educate early stage life science and healthcare companies and an audience consisting of life science ecosystem participants about how angel investing works. Although specific formats vary, at each event at least three early stage companies present a pitch deck and experienced investors provide either one-on-one coaching or direct constructive feedback intended to help the companies improve their chances of getting investment. The audience members vote on “Best in Show”. In all cases, the companies receive constructive criticism of the company’s presentation, business model and perceived viability in the market. At the end of each year, the “Best in Show” winners compete against each other for the title of “Best of the Best.” About MABA Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment. MABA recently launched a sidecar fund (https://sidecarfund.bioangels.net/) to enable co-investment by accredited non-members. Contact:

Mid Atlantic Bio Angels Investments

20 Investments

Mid Atlantic Bio Angels has made 20 investments. Their latest investment was in New View Surgical as part of their Series B on September 9, 2021.

CBI Logo

Mid Atlantic Bio Angels Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/16/2021

Series B

New View Surgical

$9M

No

2

12/10/2020

Series A

Astrocyte Pharmaceuticals

$6M

Yes

2

7/31/2019

Angel - IV

FEMSelect

No

1

6/17/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/24/2019

Angel - III

Subscribe to see more

Subscribe to see more

10

Date

9/16/2021

12/10/2020

7/31/2019

6/17/2019

5/24/2019

Round

Series B

Series A

Angel - IV

Series A

Angel - III

Company

New View Surgical

Astrocyte Pharmaceuticals

FEMSelect

Subscribe to see more

Subscribe to see more

Amount

$9M

$6M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

Mid Atlantic Bio Angels Portfolio Exits

1 Portfolio Exit

Mid Atlantic Bio Angels has 1 portfolio exit. Their latest portfolio exit was Salarius Pharmaceuticals on January 04, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/4/2019

Reverse Merger

$99M

7

Date

1/4/2019

Exit

Reverse Merger

Companies

Valuation

$99M

Acquirer

Sources

7

Mid Atlantic Bio Angels Team

3 Team Members

Mid Atlantic Bio Angels has 3 team members, including current Founding Partner, Bernard C Rudnick.

Name

Work History

Title

Status

Bernard C Rudnick

Founding Partner

Current

Yaniv Sneor

Founding Partner

Current

Bernard C. Rudnick

Founder

Former

Name

Bernard C Rudnick

Yaniv Sneor

Bernard C. Rudnick

Work History

Title

Founding Partner

Founding Partner

Founder

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.